gp100 209-217 mutant (HLA-A*02:01) 210M IMDQVPFSV
€105.00*
Description
gp100 209-217 Pos. 210M (HLA-A*02:01) IMDQVPFSV is a linear peptidic epitope studied as part of Melanoma antigen preferentially expressed in tumors from Homo sapiens (human). This epitope has been studied for immune reactivity in several publication, tested in T cell assays and MHC ligand assays. This modified gp100 peptide amino acids 209 to 217 is a MHC-associated HLA-A2.1-restricted epitope derived from melanoma antigene. It can be processed, presented, and recognized by T cells. Alteration of the gp100 209-217 peptide to gp100 209-217 Met2 at the second amino acid changing threonine to a methionine was found to increase the affinity for MHC-associated HLA-A2.1 resulting in enhanced induction of T cells reactive to native gp100
TechData
| Sequence: | IMDQVPFSV |
| Gene: | PMEL |
| Delivery: | 3 weeks |
| C-Terminus: | OH |
| N-Terminus: | H |
| Amount: | 1 mg |
| Counterion: | TFA |
| Protein: | Melanocyte protein PMEL |
| Species: | Human |
| Allele: | HLA-A*02:01 |
| Application: | T-cell assays, Immune monitoring, Antigen specific T-cell stimulation, T-cell expansion, Cellular immune response |
| Indication: | Cancer |
| Purity: | 95% HPLC-MS |
More gp100 peptides
